(Q48019730)

7 February 2018

title

Vaxfectin enhances immunogenicity and protective efficacy of P. yoelii circumsporozoite DNA vaccines (English)

1 reference

7 February 2018

author

Thomas L. Richie

10

1 reference

7 February 2018

Martha Sedegah

1

Martha Sedegah

1 reference

7 February 2018

5

Glenna Banania

1 reference

7 February 2018

Noelle B Patterson

6

Noelle Patterson

1 reference

7 February 2018

Denise L Doolan

11

Denise L Doolan

1 reference

7 February 2018

Daniel J Carucci

9

Daniel J Carucci

1 reference

7 February 2018

Arnel Belmonte

3

Arnel Belmonte

1 reference

7 February 2018

Marilyn Ferrari

7

Marilyn Ferrari

1 reference

7 February 2018

author name string

William O Rogers

2

1 reference

7 February 2018

Maria Belmonte

4

1 reference

7 February 2018

David C Kaslow

8

1 reference

7 February 2018

language of work or name

English

0 references

publication date

2 November 2005

1 reference

7 February 2018

published in

Vaccine

1 reference

7 February 2018

volume

24

1 reference

7 February 2018

issue

11

1 reference

7 February 2018

page(s)

1921-1927

1 reference

7 February 2018

DNA prime/canarypox boost-based immunotherapy of chronic hepatitis B virus infection in a chimpanzee

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.10.041

Neutralizing antibody-independent containment of immunodeficiency virus challenges by DNA priming and recombinant pox virus booster immunizations

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.10.041

Development of a preventive vaccine for Ebola virus infection in primates

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.10.041

A human immunodeficiency virus 1 (HIV-1) clade A vaccine in clinical trials: stimulation of HIV-specific T-cell responses by DNA and recombinant modified vaccinia virus Ankara (MVA) vaccines in humans

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.10.041

Phase 1 evaluation of 3 highly immunogenic prime-boost regimens, including a 12-month reboosting vaccination, for malaria vaccination in Gambian men.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.10.041

Enhanced T-cell immunogenicity of plasmid DNA vaccines boosted by recombinant modified vaccinia virus Ankara in humans

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.10.041

Enhanced T cell-mediated protection against malaria in human challenges by using the recombinant poxviruses FP9 and modified vaccinia virus Ankara

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.10.041

Induction of antigen-specific cytotoxic T lymphocytes in humans by a malaria DNA vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.10.041

A phase I trial of DNA vaccination with a plasmid expressing prostate-specific antigen in patients with hormone-refractory prostate cancer.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.10.041

Vaxfectin enhances the humoral immune response to plasmid DNA-encoded antigens

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.10.041

Vaxfectin enhances antigen specific antibody titers and maintains Th1 type immune responses to plasmid DNA immunization

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.10.041

Enhancing effect of vaxfectin on the ability of a Japanese encephalitis DNA vaccine to induce neutralizing antibody in mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.10.041

Salivary gland delivery of pDNA-cationic lipoplexes elicits systemic immune responses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.10.041

Improved tuberculosis DNA vaccines by formulation in cationic lipids

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.10.041

Human immunodeficiency virus type 2 DNA vaccine provides partial protection from acute baboon infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.10.041

A cationic lipid-formulated plasmid DNA vaccine confers sustained antibody-mediated protection against aerosolized anthrax spores

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.10.041

Immunotherapy of advanced malignancy by direct gene transfer of an interleukin-2 DNA/DMRIE/DOPE lipid complex: phase I/II experience

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.10.041

Vaccination of puppies with a lipid-formulated plasmid vaccine protects against a severe canine distemper virus challenge

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.10.041

Rabies DNA vaccine in the horse: strategies to improve serological responses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.10.041

The infectivity of Plasmodium yoelii in different strains of mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.10.041

Boosting with recombinant vaccinia increases immunogenicity and protective efficacy of malaria DNA vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.10.041

Protection against malaria by immunization with plasmid DNA encoding circumsporozoite protein

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.10.041

Induction of CD4(+) T cell-dependent CD8(+) type 1 responses in humans by a malaria DNA vaccine.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.10.041

Enhanced immunogenicity for CD8+ T cell induction and complete protective efficacy of malaria DNA vaccination by boosting with modified vaccinia virus Ankara

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.10.041

10.1016/J.VACCINE.2005.10.041

7 January 2021

Identifiers

DOI

1 reference

7 February 2018

1 reference

7 February 2018